MELVILLE, N.Y.– Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the repurchase of up to $400 million of shares of the Company’s common stock.
This program is in addition to the $400 million repurchase program announced in August 2022, which is anticipated to be fully executed by the end of the first quarter of 2023.
The Company had approximately 131.5 million shares outstanding as of February 10, 2023. This new authorization represents approximately 3.8 percent of shares outstanding at the current stock price. Purchases may be made from time to time in the open market, or through negotiated transactions.
“Henry Schein’s share repurchase program reflects our confidence in the Company’s 2022-2024 BOLD +1 Strategic Plan for sustainable growth and value creation,” said Ronald N. South, Senior Vice President and Chief Financial Officer of Henry Schein. “We are pleased that our strong balance sheet provides us with the flexibility and financial stability to pursue new markets while strengthening and broadening our comprehensive offering of health care solutions.”
